1. Pink Sheet
  2. >>Geography
  3. >>Europe

EU To Simplify ‘Increasingly Complex’ Post-Authorization Variation Procedures

 
• By Ian Schofield

Reclassifying certain variations and having more flexibility on the level of technical information required in submissions are among ideas put forward by the European Commission in its latest consultation.

Line from A straight to the point B. The concept of simplify
The EU is to simplify processes for making changes to marketing authorizations • Source: Shutterstock

The European Commission has drawn up plans to reduce the administrative burden on pharma firms and regulatory authorities caused by the growing number of applications for variations to marketing authorizations (MAs).

The proposals, which would streamline the current framework and speed up the handling of variation applications, have just been...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Europe

EU Critical Medicines Act May Include Investigational Products & Mandatory Redistribution Measure

 
• By Neena Brizmohun

The inclusion of investigational drugs in the Critical Medicines Act and new provisions on stockpiling are among the raft of amendments the European Parliament has made to the draft legislation.

EU HTA Regulation: Key Gaps Identified In Support For Small Companies And Experts

 
• By Eliza Slawther

A meeting between the European Commission and industry stakeholders has revealed several areas of importance and lessons learned in relation to the EU Health Technology Assessment Regulation, which began to apply to certain medicinal products this year.

New EU Filings

 
• By Neena Brizmohun

Insulin efsitora alfa, Eli Lilly’s once-weekly, subcutaneous treatment for type 2 diabetes, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.

First-Of-A-Kind Nasal Spray For Pain In Children Among 13 New EU Filings

 
• By Neena Brizmohun

Cessatech and Proveca’s investigational, sufentanil/ketamine fixed-dose combination analgesic nasal spray is among the latest drugs that the European Medicines Agency has started to review for potential pan-EU marketing authorization.

More from Geography

EU Critical Medicines Act May Include Investigational Products & Mandatory Redistribution Measure

 
• By Neena Brizmohun

The inclusion of investigational drugs in the Critical Medicines Act and new provisions on stockpiling are among the raft of amendments the European Parliament has made to the draft legislation.

EU HTA Regulation: Key Gaps Identified In Support For Small Companies And Experts

 
• By Eliza Slawther

A meeting between the European Commission and industry stakeholders has revealed several areas of importance and lessons learned in relation to the EU Health Technology Assessment Regulation, which began to apply to certain medicinal products this year.

89 Complete Response Letters For Unapproved Drugs, One Huge Leap For US FDA Transparency

 
• By Bridget Silverman

The US FDA’s unprecedented publication of 89 recent CRLs for unapproved products comes with a promise to release future letters more promptly.